Glycosylation of therapeutic proteins: An effective strategy to optimize efficacy

BioDrugs

Volumn 24, Issue 1, 2010, Pages 9-21

  Solá, Ricardo J ^a   Griebenow, Kai ^a  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ALGLUCERASE; ALPHA 1 ANTITRYPSIN; ALPHAN3 INTERFERON; ALTEPLASE; BETA1A INTERFERON; COMPLEMENT COMPONENT C1S INHIBITOR; DORNASE ALFA; DROTRECOGIN; FOLLISTIM AQ; GALSULFASE; HAEMOCOMPLETTAN; HYALURONIDASE; HYLENEX; IDURONATE 2 SULFATASE; IMIGLUCERASE; LARONIDASE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLASMINOGEN ACTIVATOR; PROTEIN; RECOMBINANT ANTITHROMBIN III; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT LUTEINIZING HORMONE; RECOMBINANT THYROTROPIN; TENECTEPLASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE HEART INFARCTION; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANEMIA; ANGIONEUROTIC EDEMA; BLEEDING; CHRONIC KIDNEY FAILURE; CONDYLOMA ACUMINATUM; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; EMPHYSEMA; ENZYME ACTIVITY; EXTERNAL CONDYLOMATA ACUMINATA; FABRY DISEASE; FEMALE INFERTILITY; GAUCHER DISEASE; GLYCOGEN STORAGE DISEASE TYPE 2; HEMOPHILIA A; HEMOPHILIA B; HUMAN; HURLER SYNDROME; HYPOTHYROIDISM; IN VITRO STUDY; IN VIVO STUDY; LUNG EMBOLISM; MAROTEAUX LAMY SYNDROME; MOLECULAR STABILITY; MULTIPLE SCLEROSIS; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PHYSICAL CHEMISTRY; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN GLYCOSYLATION; PROTEIN PURIFICATION; REVIEW; SEPSIS; THROMBOEMBOLISM; THYROID CANCER;

ANIMALS; DRUG DELIVERY SYSTEMS; GLYCOSYLATION; HUMANS; PROTEIN ENGINEERING; PROTEINS;

EID: 75149183678     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11530550-000000000-00000     Document Type: Review

References (234)

1. Andersen DC, Krummen L. Recombinant protein expression for therapeutic applications. Curr Opin Biotechnol 2002; 13 (2): 117-123
2. Carpenter JF, Manning MC, Randolph TW. Long-term storage of proteins. Curr Protoc Protein Sci 2002; Suppl. 27: 4.6.1-4.6.6
3. Hawe A, Friess W. Formulation development for hydrophobic therapeutic proteins. Pharm Dev Technol 2007; 12 (3): 223-237
4. Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 1999; 185 (2): 129-188
5. Frokjaer S, Otzen DE. Protein drug stability: a formulation challenge. Nature Rev Drug Discov 2005; 4 (4): 298-306
6. Manning MC, Patel K, Borchardt RT. Stability of protein pharmaceuticals. Pharm Res 1989; 6 (11): 903-918
7. Davis GC. Protein stability: impact upon protein pharmaceuticals [letter]. Biologicals 1993; 21 (2): 105
8. Krishnamurthy R, Manning MC. The stability factor: importance in formulation development. Curr Pharm Biotechnol 2002; 3 (4): 361-371
9. Arakawa T, Prestrelski SJ, Kenney WC, et al. Factors affecting short-term and long-termstabilities of proteins.AdvDrugDelivRev 2001; 46 (1-3): 307-326
10. Lee JC. Biopharmaceutical formulation. Curr Opin Biotechnol 2000; 11 (1): 81-84
11. Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm 2005; 289 (1-2): 1-30
12. Patro SY, Freund E, Chang BS. Protein formulation and fill-finish operations. Biotechnol Annu Rev 2002; 8: 55-84
13. Solá RJ, Griebenow K. Effects of glycosylation on the stability of protein pharmaceuticals. J Pharm Sci 2009; 98 (4): 1223-1245
14. Brown LR. Commercial challenges of protein drug delivery. Expert Opin Drug Deliv 2005; 2 (1): 29-42
15. Mahmood I, Green MD. Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clin Pharmacokinet 2005; 44 (4): 331-347
16. Tang L, Persky AM, Hochhaus G, et al. Pharmacokinetic aspects of biotechnology products. J Pharm Sci 2004; 93 (9): 2184-2204
17. Beals JM, Shanafelt AB. Enhancing exposure of protein therapeutics. Drug Discov Today Technol 2006; 3 (1): 87-94
18. Marshall SA, Lazar GA, Chirino AJ, et al. Rational design and engineering of therapeutic proteins. Drug Discov Today 2003; 8 (5): 212-221
19. Lazar GA, Marshall SA, Plecs JJ, et al. Designing proteins for therapeutic applications. Curr Opin Struct Biol 2003; 13 (4): 513-518
20. Jefferis R. Glycosylation of recombinant antibody therapeutics. Biotechnol Prog 2005; 21 (1): 11-16
21. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009; 8 (3): 226-234
22. Jefferis R. Glycosylation of antibody therapeutics: optimization for purpose. Methods Mol Biol 2009; 483: 223-238
23. Byrne B, Donohoe GG, O'Kennedy R. Sialic acids: carbohydrate moieties that influence the biological and physical properties of biopharmaceutical proteins and living cells. Drug Discov Today 2007; 12 (7-8): 319
24. Sinclair AM, Elliott S. Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J Pharm Sci 2005; 94 (8): 1626-1635
25. Elliott S, Lorenzini T, Asher S, et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 2003; 21 (4): 414-421
26. Ceaglio N, Etcheverrigaray M, Kratje R, et al. Novel long-lasting interferon alpha derivatives designed by glycoengineering. Biochimie 2008; 90 (3): 437-449
27. Koury MJ. Sugar coating extends half-lives and improves effectiveness of cytokine hormones. Trends Biotechnol 2003; 21 (11): 462-464
28. Raju TS, Briggs JB, Chamow SM, et al. Glycoengineering of therapeutic glycoproteins: in vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues. Biochemistry 2001; 40 (30): 8868-8876
29. Beck A, Wagner-Rousset E, Bussat MC, et al. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr Pharm Biotechnol 2008; 9 (6): 482-501
30. Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm 2000; 203 (1-2): 1-60
31. Wang W, Singh S, Zeng DL, et al. Antibody structure, instability, and formulation. J Pharm Sci 2007; 96 (1): 1-26
32. Volkin DB, Mach H, Middaugh CR. Degradative covalent reactions important to protein stability. Mol Biotechnol 1997; 8 (2): 105-122
33. Pace CN. Conformational stability of globular proteins. Trends Biochem Sci 1990; 15 (1): 14-17
34. XieM, Schowen RL. Secondary structure and protein deamidation. J Pharm Sci 1999; 88 (1): 8-13
35. Pace CN. Measuring and increasing protein stability. Trends Biotechnol 1990; 8 (4): 93-98
36. Valente JJ, Payne RW, Manning MC, et al. Colloidal behavior of proteins: effects of the second virial coefficient on solubility, crystallization and aggregation of proteins in aqueous solution. Curr Pharm Biotechnol 2005; 6 (6): 427-436
37. Chi EY, Krishnan S, Kendrick BS, et al. Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony-stimulating factor. Protein Sci 2003; 12 (5): 903-913
38. Kueltzo LA, Wang W, Randolph TW, et al. Effects of solution conditions, processing parameters, and container materials on aggregation of a monoclonal antibody during freeze-thawing. J Pharm Sci 2008; 97 (5): 1801-1812
39. Cromwell ME, Hilario E, Jacobson F. Protein aggregation and bioprocessing. AAPS J 2006; 8 (3): E572-9
40. Roberts CJ. Non-native protein aggregation kinetics. Biotechnol Bioeng 2007; 98 (5): 927-938
41. Strober W, Waldmann TA. The role of the kidney in the metabolism of plasma proteins. Nephron 1974; 13 (1): 35-66
42. Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly (ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2003; 55 (10): 1261-1277
43. Weinstein T, Gafter U, Chagnac A, et al. Distribution of glycosaminoglycans in rat renal tubular epithelium. J Am Soc Nephrol 1997; 8 (4): 586-595
44. Choi HS, Liu W, Misra P, et al. Renal clearance of quantum dots. Nat Biotechnol 2007; 25 (10): 1165-1170
45. Montastruc JL, Galitzky J, Berlan M, et al. Mechanism of receptor regulation during repeated administration of drugs. Therapie 1993; 48 (5): 421-426
46. Laduron PM. From receptor internalization to nuclear translocation: new targets for long-term pharmacology. Biochem Pharmacol 1994; 47 (1): 3-13
47. Walsh G. Second-generation biopharmaceuticals. Eur J Pharm Biopharm 2004; 58 (2): 185-196
48. Grabenhorst E, Schlenke P, Pohl S, et al. Genetic engineering of recombinant glycoproteins and the glycosylation pathway in mammalian host cells. Glycoconj J 1999; 16 (2): 81-97
49. Solá RJ, Rodriguez-Martinez JA, Griebenow K. Modulation of protein biophysical properties by chemical glycosylation: biochemical insights and biomedical implications. Cell Mol Life Sci 2007; 64 (16): 2133-2152
50. Liu DT. Glycoprotein pharmaceuticals: scientific and regulatory considerations, and the US Orphan Drug Act. Trends Biotechnol 1992; 10 (4): 114-120
51. Weerapana E, Imperiali B. Asparagine-linked protein glycosylation: from eukaryotic to prokaryotic systems. Glycobiology 2006; 16 (6): 91-101R
52. Mann M, Jensen ON. Proteomic analysis of post-translational modifications. Nature Biotechnol 2003; 21 (3): 255-261
53. Walsh CT, Garneau-Tsodikova S, Gatto GJ. Protein posttranslational modifications: the chemistry of proteome diversifications. Angewandte Chemie Int Ed 2005; 44 (45): 7342-7372
54. Apweiler R, Hermjakob H, Sharon N. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochim Biophys Acta 1999; 1473 (1): 4-8
55. Sears P, Wong CH. Enzyme action in glycoprotein synthesis. Cell Mol Life Sci 1998; 54 (3): 223-252
56. Lehle L, Strahl S, Tanner W. Protein glycosylation, conserved from yeast to man: a model organism helps elucidate congenital human diseases. Angew Chem Int Ed Engl 2006; 45 (41): 6802-6818
57. Medzihradszky KF. Characterization of protein N-glycosylation. Methods Enzymol 2005; 405: 116-138
58. Peter-Katalinic J. Methods in enzymology: O-glycosylation of proteins. Methods Enzymol 2005; 405: 139-171
59. Hossler P, Mulukutla BC, Hu WS. Systems analysis of N-glycan processing in mammalian cells. PLoS One 2007; 2 (1): e713
60. Sethuraman N, Stadheim TA. Challenges in therapeutic glycoprotein production. Curr Opin Biotechnol 2006; 17 (4): 341-346
61. Hsieh-Wilson LC. Tailor-made glycoproteins. Trends Biotechnol 2004; 22 (10): 489-491
62. Rich JR,Withers SG. Emerging methods for the production of homogeneous human glycoproteins. Nat Chem Biol 2009; 5 (4): 206-215
63. Tarp MA, Clausen H. Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim Biophys Acta 2008; 1780 (3): 546-563
64. Brik A, Ficht S, Wong CH. Strategies for the preparation of homogenous glycoproteins. Curr Opin Chem Biol 2006; 10 (6): 638-644
65. Grogan MJ, Pratt MR, Marcaurelle LA, et al. Homogeneous glycopeptides and glycoproteins for biological investigation. Annu Rev Biochem 2002; 71: 593-634
66. Gamblin DP, Scanlan EM, Davis BG. Glycoprotein synthesis: an update. Chem Rev 2009; 109 (1): 131-163
67. van Kasteren SI, Kramer HB, Gamblin DP, et al. Site-selective glycosylation of proteins: creating synthetic glycoproteins.Nat Protoc 2007; 2 (12): 3185-3194
68. Geng J, Mantovani G, Tao L, et al. Site-directed conjugation of 'clicked' glycopolymers to form glycoprotein mimics: binding to mammalian lectin and induction of immunological function. J Am Chem Soc 2007; 129 (49): 15156-15163
69. Vazquez-Dorbatt V, Maynard HD. Biotinylated glycopolymers synthesized by atom transfer radical polymerization. Biomacromolecules 2006; 7 (8): 2297-2302
70. Vazquez-Dorbatt V, Tolstyka ZP, Chang CW, et al. Synthesis of a pyridyl disulfide end-functionalized glycopolymer for conjugation to biomolecules and patterning on gold surfaces. Biomacromolecules 2009; 10 (8): 2207-2212
71. Choi BK, Bobrowicz P, Davidson RC, et al. Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris. Proc Natl Acad Sci U S A 2003; 100 (9): 5022-5027
72. Li H, Sethuraman N, Stadheim TA, et al. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotechnol 2006; 24 (2): 210-215
73. Hamilton SR, Bobrowicz P, Bobrowicz B, et al. Production of complex human glycoproteins in yeast. Science 2003; 301 (5637): 1244-1246
74. Hamilton SR, Davidson RC, Sethuraman N, et al. Humanization of yeast to produce complex terminally sialylated glycoproteins. Science 2006; 313 (5792): 1441-1443
75. Potgieter TI, Cukan M, Drummond JE, et al. Production of monoclonal antibodies by glycoengineered Pichia pastoris. J Biotechnol 2009; 139 (4): 318-325
76. Chiba Y, Jigami Y. Production of humanized glycoproteins in bacteria and yeasts. Curr Opin Chem Biol 2007; 11 (6): 670-676
77. Karg SR, Kallio PT. The production of biopharmaceuticals in plant systems. Biotechnol Adv 2009; 27 (6): 879-894
78. Hossler P, Khattak SF, Li ZJ. Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology 2009; 19 (9): 936-949
79. Chiba Y, Akeboshi H. Glycan engineering and production of 'humanized' glycoprotein in yeast cells. Biol Pharm Bull 2009; 32 (5): 786-795
80. Ballew N, Gerngross T. Production of therapeutic proteins in fungal hosts. Expert Opin Biol Ther 2004; 4 (5): 623-626
81. Gerngross TU. Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nat Biotechnol 2004; 22 (11): 1409-1414
82. Bork K, Horstkorte R, Weidemann W. Increasing the sialylation of therapeutic glycoproteins: the potential of the sialic acid biosynthetic pathway. J Pharm Sci 2009; 98 (10): 3499-3508
83. Werner RG, Kopp K, Schlueter M. Glycosylation of therapeutic proteins in different production systems. Acta Paediatr Suppl 2007; 96 (455): 17-22
84. Langdon RH, Cuccui J, Wren BW. N-linked glycosylation in bacteria: an unexpected application. Future Microbiol 2009; 4 (4): 401-412
85. Ko K, Ahn MH, Song M, et al. Glyco-engineering of biotherapeutic proteins in plants. Mol Cells 2008; 25 (4): 494-503
86. Mohan C, Kim YG, Koo J, et al. Assessment of cell engineering strategies for improved therapeutic protein production in CHO cells. Biotechnol J 2008; 3 (5): 624-630
87. Shi X, Jarvis DL. Protein N-glycosylation in the baculovirus-insect cell system. Curr Drug Targets 2007; 8 (10): 1116-1125
88. Hamilton SR, Gerngross TU. Glycosylation engineering in yeast: the advent of fully humanized yeast. Curr Opin Biotechnol 2007; 18 (5): 387-392
89. Ioannou YA, Zeidner KM, Grace ME, et al. Human alpha-galactosidase A: glycosylation site 3 is essential for enzyme solubility. Biochem J 1998; 332 (Pt 3): 789-797
90. Clark SE, Muslin EH, Henson CA. Effect of adding and removing N-glycosylation recognition sites on the thermostability of barley alpha-glucosidase. Protein Eng Des Sel 2004; 17 (3): 245-249
91. Kwon KS, Yu MH. Effect of glycosylation on the stability of alpha1-antitrypsin toward urea denaturation and thermal deactivation. Biochim Biophys Acta 1997; 1335 (3): 265-272
92. Sundaram PV, Venkatesh R. Retardation of thermal and urea induced inactivation of alpha-chymotrypsin by modification with carbohydrate polymers. Protein Eng 1998; 11 (8): 699-705
93. Solá RJ,Al-Azzam W, Griebenow K. Engineering of protein thermodynamic, kinetic, and colloidal stability: chemical glycosylation with monofunctionally activated glycans. Biotechnol Bioeng 2006; 94 (6): 1072-1079
94. van Zuylen CW, de Beer T, Leeflang BR, et al. Mobilities of the inner three core residues and the Man (alpha 1-6) branch of the glycan at Asn78 of the alpha-subunit of human chorionic gonadotropin are restricted by the protein. Biochemistry 1998; 37 (7): 1933-1940
95. Uchida E, Morimoto K, Kawasaki N, et al. Effect of active oxygen radicals on protein and carbohydrate moieties of recombinant human erythropoietin. Free Radic Res 1997; 27 (3): 311-323
96. Narhi LO, Arakawa T, Aoki KH, et al. The effect of carbohydrate on the structure and stability of erythropoietin. J Biol Chem 1991; 266 (34): 23022-23026
97. Tsuda E, Kawanishi G, Ueda M, et al. The role of carbohydrate in recombinant human erythropoietin. Eur J Biochem 1990; 188 (2): 405-411
98. Runkel L, Meier W, Pepinsky RB, et al. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm Res 1998; 15 (4): 641-649
99. Karpusas M, Whitty A, Runkel L, et al. The structure of human interferonbeta: implications for activity. Cell Mol Life Sci 1998; 54 (11): 1203-1216
100. Conradt HS, Egge H, Peter-Katalinic J, et al. Structure of the carbohydrate moiety of human interferon-beta secreted by a recombinant Chinese hamster ovary cell line. J Biol Chem 1987; 262 (30): 14600-14605
101. Rudd PM, Joao HC, Coghill E, et al. Glycoforms modify the dynamic stability and functional activity of an enzyme. Biochemistry 1994; 33 (1): 17-22
102. Kim BM, Kim H, Raines RT, et al. Glycosylation of onconase increases its conformational stability and toxicity for cancer cells. Biochem Biophys Res Commun 2004; 315 (4): 976-983
103. Nissen C. Glycosylation of recombinant human granulocyte colony stimulating factor: implications for stability and potency. Eur J Cancer 1994; 30A Suppl. 3: S12-4
104. Oh-eda M, Hasegawa M, Hattori K, et al. O-linked sugar chain of human granulocyte colony-stimulating factor protects it against polymerization and denaturation allowing it to retain its biological activity. J Biol Chem 1990; 265 (20): 11432-11435
105. Ono M. Physicochemical and biochemical characteristics of glycosylated recombinant human granulocyte colony stimulating factor (lenograstim). Eur J Cancer 1994; 30A Suppl. 3: S7-11
106. Weintraub BD, Stannard BS,Meyers L. Glycosylation of thyroid-stimulating hormone in pituitary tumor cells: influence of high mannose oligosaccharide units on subunit aggregation, combination, and intracellular degradation. Endocrinology 1983; 112 (4): 1331-1345
107. Yang B, Li TD. Effect of glycosylation at Asn302 of pro-urokinase on its stability in culture supernatant. Chin Med Sci J 2006; 21 (2): 128-130
108. Baudys M, Uchio T, Mix D, et al. Physical stabilization of insulin by glycosylation. J Pharm Sci 1995; 84 (1): 28-33
109. Liu H, Bulseco GG, Sun J. Effect of posttranslational modifications on the thermal stability of a recombinant monoclonal antibody. Immunol Lett 2006; 106 (2): 144-153
110. Ghirlando R, Lund J, Goodall M, et al. Glycosylation of human IgG-Fc: influences on structure revealed by differential scanning micro-calorimetry. Immunol Lett 1999; 68 (1): 47-52
111. Lis H, Sharon N. Protein glycosylation. Structural and functional aspects. Eur J Biochem 1993; 218 (1): 1-27
112. Varki A. Biological roles of oligosaccharides: all of the theories are correct. Glycobiology 1993; 3 (2): 97-130
113. Vegarud G, Christensen TB. The resistance of glycoproteins to proteolytic inactivation. Acta Chem Scand B 1975; 29 (8): 887-888
114. Vegarud G, Christnsen TB. Glycosylation of proteins: a new method of enzyme stabilization. Biotechnol Bioeng 1975; 17 (9): 1391-1397
115. Ueda T, Tomita K, Notsu Y, et al. Chemoenzymatic synthesis of glycosylated glucagon-like peptide 1: effect of glycosylation on proteolytic resistance and in vivo blood glucose-lowering activity. JAmChemSoc 2009; 131 (17): 6237-6245
116. Carter CR, Keeble JR, Thorpe R. Human serum inactivates non-glycosylated but not glycosylated granulocyte colony stimulating factor by a protease dependent mechanism: significance of carbohydrates on the glycosylated molecule. Biologicals 2004; 32 (1): 37-47
117. Wicker-Planquart C, Canaan S, Riviere M, et al. Site-directed removal of N-glycosylation sites in human gastric lipase. Eur J Biochem 1999; 262 (3): 644-651
118. Grinnell BW, Walls JD, Gerlitz B. Glycosylation of human protein C affects its secretion, processing, functional activities, and activation by thrombin. J Biol Chem 1991; 266 (15): 9778-9785
119. Wang P, Zhang J, Sun Z, et al. Glycosylation of prourokinase produced by Pichia pastoris impairs enzymatic activity but not secretion. Protein Expr Purif 2000; 20 (2): 179-185
120. Sareneva T, Cantell K, Pyhala L, et al. Effect of carbohydrates on the pharmacokinetics of human interferon-gamma. J Interferon Res 1993; 13 (4): 267-269
121. Raju TS, Scallon B. Fc glycans terminated with N-acetylglucosamine residues increase antibody resistance to papain. Biotechnol Prog 2007; 23 (4): 964-971
122. Clowers BH, Dodds ED, Seipert RR, et al. Site determination of protein glycosylation based on digestion with immobilized nonspecific proteases and Fourier transform ion cyclotron resonance mass spectrometry. J Proteome Res 2007; 6 (10): 4032-4040
123. Ashwell G, Morell A. The dual role of sialic acid in the hepatic recognition and catabolism of serum glycoproteins. Biochem Soc Symp 1974; (40): 117-124
124. Ashwell G, Morell AG. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv Enzymol Relat Areas Mol Biol 1974; 41 (0): 99-128
125. Stockert RJ, Morell AG, Ashwell G. Structural characteristics and regulation of the asialoglycoprotein receptor. Targeted Diagn Ther 1991; 4: 41-64
126. Pricer Jr WE, Hudgin RL, Ashwell G, et al. A membrane receptor protein for asialoglycoproteins. Methods Enzymol 1974; 34: 688-691
127. Morell AG, Irvine RA, Sternlieb I, et al. Physical and chemical studies on ceruloplasmin, V: metabolic studies on sialic acid-free ceruloplasmin in vivo. J Biol Chem 1968; 243 (1): 155-159
128. Gross V,Heinrich PC, vom Berg D, et al. Involvement of various organs in the initial plasma clearance of differently glycosylated rat liver secretory proteins. Eur J Biochem 1988; 173 (3): 653-659
129. Morell AG, Gregoriadis G, Scheinberg IH, et al. The role of sialic acid in determining the survival of glycoproteins in the circulation. J Biol Chem 1971; 246 (5): 1461-1467
130. Baynes JW, Wold F. Effect of glycosylation on the in vivo circulating half-life of ribonuclease. J Biol Chem 1976; 251 (19): 6016-6024
131. Wileman T, Harding C, Stahl P. Receptor-mediated endocytosis. Biochem J 1985; 232 (1): 1-14
132. Schlesinger PH, Doebber TW, Mandell BF, et al. Plasma clearance of glycoproteins with terminal mannose and N-acetylglucosamine by liver nonparenchymal cells: studies with beta-glucuronidase, N-acetyl-beta-D- glucosaminidase, ribonuclease B and agalacto-orosomucoid. Biochem J 1978; 176 (1): 103-109
133. Schlesinger PH, Rodman JS, Doebber TW, et al. The role of extra-hepatic tissues in the receptor-mediated plasma clearance of glycoproteins terminated by mannose or N-acetylglucosamine. Biochem J 1980; 192 (2): 597-606
134. Townsend R, Stahl P. Isolation and characterization of a mannose/N-acetylglucosamine/ fucose-binding protein from rat liver. Biochem J 1981; 194 (1): 209-214
135. Achord DT, Brot FE, Bell CE, et al. Human beta-glucuronidase: in vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells. Cell 1978; 15 (1): 269-278
136. Weigel PH, Yik JH. Glycans as endocytosis signals: the cases of the asialoglycoprotein and hyaluronan/chondroitin sulfate receptors. Biochim Biophys Acta 2002; 1572 (2-3): 341-363
137. Jefferis R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol Sci 2009; 30 (7): 356-362
138. Egleton RD, Mitchell SA, Huber JD, et al. Improved bioavailability to the brain of glycosylatedMet-enkephalin analogs. Brain Res 2000; 881 (1): 37-46
139. Egleton RD, Mitchell SA, Huber JD, et al. Improved blood-brain barrier penetration and enhanced analgesia of an opioid peptide by glycosylation. J Pharmacol Exp Ther 2001; 299 (3): 967-972
140. Kihlberg J, Ahman J, Walse B, et al. Glycosylated peptide hormones: pharmacological properties and conformational studies of analogues of [1-desamino, 8-D-arginine]vasopressin. J Med Chem 1995; 38 (1): 161-169
141. Haubner R, Wester HJ, Burkhart F, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001; 42 (2): 326-336
142. Albert R, Marbach P, Bauer W, et al. SDZ CO 611: a highly potent glycated analog of somatostatin with improved oral activity.Life Sci 1993; 53 (6): 517-525
143. Halstenson CE, Macres M, Katz SA, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 1991; 50 (6): 702-712
144. Sasayama S,MoriyaK, Chiba T, et al.Glycosylated human interleukin-1alpha, neoglyco IL-1alpha, coupled with N-acetylneuraminic acid exhibits selective activities in vivo and altered tissue distribution.Glycoconj J 2000; 17 (6): 353-359
145. Iwao Y, Hiraike M, Kragh-Hansen U, et al. Altered chain-length and glycosylation modify the pharmacokinetics of human serum albumin. Biochim Biophys Acta 2009; 1794 (4): 634-641
146. Millward TA, Heitzmann M, Bill K, et al. Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice. Biologicals 2008; 36 (1): 41-47
147. Sheffield WP, Marques JA, Bhakta V, et al. Modulation of clearance of recombinant serum albumin by either glycosylation or truncation. Thromb Res 2000; 99 (6): 613-621
148. Cousin P, Dechaud H, Grenot C, et al. Influence of glycosylation on the clearance of recombinant human sex hormone-binding globulin from rabbit blood. J Steroid Biochem Mol Biol 1999; 70 (4-6): 115-121
149. Burgon PG, Stanton PG, Robertson DM. In vivo bioactivities and clearance patterns of highly purified human luteinizing hormone isoforms. Endocrinology 1996; 137 (11): 4827-4836
150. Wawrzynczak EJ, Cumber AJ, Parnell GD, et al. Blood clearance in the rat of a recombinant mouse monoclonal antibody lacking the N-linked oligosaccharide side chains of the CH2 domains. Mol Immunol 1992; 29 (2): 213-220
151. Henkin J, Dudlak D, Beebe DP, et al. High sialic acid content slows prourokinase turnover in rabbits. Thromb Res 1991; 63 (2): 215-225
152. Kawatsu M, Takeo K, Kajikawa T, et al. The pharmacokinetic pattern of glycosylated human recombinant lymphotoxin (LT) in rats after intravenous administration. J Pharmacobiodyn 1990; 13 (9): 549-557
153. Gross V, Steube K, Tran-Thi T, et al. The role of N-glycosylation for the plasma clearance of rat liver secretory glycoproteins. Eur J Biochem 1987; 162 (1): 83-88
154. Kim HJ, Lee DH, Kim DK, et al. The glycosylation and in vivo stability of human granulocyte-macrophage colony-stimulating factor produced in rice cells. Biol Pharm Bull 2008; 31 (2): 290-294
155. Denis CV, Christophe OD, Oortwijn BD, et al. Clearance of von Willebrand factor. Thromb Haemost 2008; 99 (2): 271-278
156. Millar CM, Riddell AF, Brown SA, et al. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations. Thromb Haemost 2008; 99 (5): 916-924
157. Smith WB, Dowell JA, Pratt RD. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease. Clin Ther 2007; 29 (7): 1368-1380
158. Jones AJ, Papac DI, Chin EH, et al. Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. Glycobiology 2007; 17 (5): 529-540
159. Perlman S, van den Hazel B, Christiansen J, et al. Glycosylation of an Nterminal extension prolongs the half-life and increases the in vivo activity of follicle stimulating hormone. J Clin Endocrinol Metab 2003; 88 (7): 3227-3235
160. Barrios-De-Tomasi J, Timossi C, MerchantH, et al. Assessment of the in vitro and in vivo biological activities of the human follicle-stimulating isohormones. Mol Cell Endocrinol 2002; 186 (2): 189-198
161. Macdougall IC.Optimizing the use of erythropoietic agents: pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant 2002; 17 Suppl. 5: 66-70
162. Ni H, Blajchman MA, Ananthanarayanan VS, et al. Mutation of any site of N-linked glycosylation accelerates the in vivo clearance of recombinant rabbit antithrombin. Thromb Res 2000; 99 (4): 407-415
163. Marinaro JA, Casley DJ, Bach LA. O-glycosylation delays the clearance of human IGF-binding protein-6 from the circulation. Eur J Endocrinol 2000; 142 (5): 512-516
164. Chitlaru T, Kronman C, Zeevi M, et al. Modulation of circulatory residence of recombinant acetylcholinesterase through biochemical or genetic manipulation of sialylation levels. Biochem J 1998; 336 (Pt 3): 647-658
165. Saxena A, Raveh L, Ashani Y, et al. Structure of glycan moieties responsible for the extended circulatory life time of fetal bovine serum acetylcholinesterase and equine serum butyrylcholinesterase. Biochemistry 1997; 36 (24): 7481-7489
166. Thotakura NR, Szkudlinski MW, Weintraub BD. Structure-function studies of oligosaccharides of recombinant human thyrotrophin by sequential deglycosylation and resialylation. Glycobiology 1994; 4 (4): 525-533
167. OtterM, Kuiper J, van Berkel TJ, et al. Mechanisms of tissue-type plasminogen activator (tPA) clearance by the liver. Ann N Y Acad Sci 1992; 667: 431-442
168. Wasley LC, Timony G, Murtha P, et al. The importance of N- and O-linked oligosaccharides for the biosynthesis and in vitro and in vivo biologic activities of erythropoietin. Blood 1991; 77 (12): 2624-2632
169. Galway AB, Hsueh AJ, Keene JL, et al. In vitro and in vivo bioactivity of recombinant human follicle-stimulating hormone and partially deglycosylated variants secreted by transfected eukaryotic cell lines. Endocrinology 1990; 127 (1): 93-100
170. Lucore CL, Fry ET, Nachowiak DA, et al. Biochemical determinants of clearance of tissue-type plasminogen activator from the circulation. Circulation 1988; 77 (4): 906-914
171. Mirshahi M, Soria J, Soria C, et al. Glycosylation of human fibrinogen and fibrin in vitro: its consequences on the properties of fibrin (ogen). Thromb Res 1987; 48 (3): 279-289
172. Elliott S, Egrie J, Browne J, et al. Control of rHuEPO biological activity: the role of carbohydrate. Exp Hematol 2004; 32 (12): 1146-1155
173. Negri L, Melchiorri P, Rocchi R, et al. Opioid receptor affinity and analgesic activity of O- and C-glycosylated opioid peptides. Acta Physiol Hung 1996; 84 (4): 441-443
174. Fishburn CS. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci 2008; 97 (10): 4167-4183
175. Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008; 20 (4): 471-478
176. Crispin M, Bowden TA, Coles CH, et al. Carbohydrate and domain architecture of an immature antibody glycoform exhibiting enhanced effector functions. J Mol Biol 2009; 387 (5): 1061-1066
177. Barbey F, HayozD,Widmer U, et al. Efficacy of enzyme replacement therapy in Fabry disease. Curr Med Chem Cardiovasc Hematol Agents 2004; 2 (4): 277-286
178. Beck M. Agalsidase alfa for the treatment of Fabry disease: new data on clinical efficacy and safety. Expert Opin Biol Ther 2009; 9 (2): 255-261
179. LeeK, Jin X, ZhangK, et al.A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 2003; 13 (4): 305-313
180. Keating GM, Simpson D. Spotlight on agalsidase beta in Fabry disease. Biodrugs 2007; 21 (4): 269-271
181. Keating GM, Simpson D. Agalsidase beta: a review of its use in the management of Fabry disease. Drugs 2007; 67 (3): 435-455 (Pubitemid 46437099)
182. Jurado Garcia JM, Torres Sanchez E, OlmosHidalgo D, et al. Erythropoietin pharmacology. Clin Transl Oncol 2007; 9 (11): 715-722
183. Takeuchi M, Kobata A. Structures and functional roles of the sugar chains of human erythropoietins. Glycobiology 1991; 1 (4): 337-346
184. Weenen C, Pena JE, Pollak SV, et al. Long-acting follicle-stimulating hormone analogs containing N-linked glycosylation exhibited increased bioactivity compared with o-linked analogs in female rats. J Clin Endocrinol Metab 2004; 89 (10): 5204-5212
185. Creus S, Chaia Z, Pellizzari EH, et al. Human FSH isoforms: carbohydrate complexity as determinant of in-vitro bioactivity. Mol Cell Endocrinol 2001; 174 (1-2): 41-49
186. le Cotonnec JY, Loumaye E, Porchet HC, et al. Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinizing hormone and recombinant human follicle-stimulating hormone. Fertil Steril 1998; 69 (2): 201-209 (Pubitemid 28117094)
187. le Cotonnec JY, Porchet HC, Beltrami V, et al. Clinical pharmacology of recombinant human luteinizing hormone, part II: bioavailability of recombinant human luteinizing hormone assessed with an immunoassay and an in vitro bioassay. Fertil Steril 1998; 69 (2): 195-200
188. le Cotonnec JY, Porchet HC, Beltrami V, et al. Clinical pharmacology of recombinant human luteinizing hormone, part I: pharmacokinetics after intravenous administration to healthy female volunteers and comparison with urinary human luteinizing hormone. Fertil Steril 1998; 69 (2): 189-194
189. Klett D, Bernard S, Lecompte F, et al. Fast renal trapping of porcine luteinizing hormone (pLH) shown by 123I-scintigraphic imaging in rats explains its short circulatory half-life. Reprod Biol Endocrinol 2003; 1: 64
190. Dhillon S, Keating GM. Lutropin alfa. Drugs 2008; 68 (11): 1529-1540
191. Baenziger JU, Kumar S, Brodbeck RM, et al. Circulatory half-life but not interaction with the lutropin/chorionic gonadotropin receptor is modulated by sulfation of bovine lutropin oligosaccharides. Proc Natl Acad Sci U S A 1992; 89 (1): 334-338
192. Wakefield LM, Winokur TS, Hollands RS, et al. Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution. J Clin Invest 1990; 86 (6): 1976-1984
193. Hoglund M. Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF): what is the difference? Med Oncol 1998; 15 (4): 229-233
194. Hovgaard D, Mortensen BT, Schifter S, et al. Comparative pharmacokinetics of single-dose administration of mammalian and bacterially-derived recombinant human granulocyte-macrophage colony-stimulating factor. Eur J Haematol 1993; 50 (1): 32-36
195. Sylvester RK. Clinical applications of colony-stimulating factors: a historical perspective. Am J Health Syst Pharm 2002; 59 (7 Suppl. 2): S6-12
196. Ziltener HJ, Clark-Lewis I, Jones AT, et al. Carbohydrate does not modulate the in vivo effects of injected interleukin-3. Exp Hematol 1994; 22 (11): 1070-1075
197. Fukushima K, Watanabe H, Takeo K, et al. N-linked sugar chain structure of recombinant human lymphotoxin produced by CHO cells: the functional role of carbohydrate as to its lectin-like character and clearance velocity. Arch Biochem Biophys 1993; 304 (1): 144-153
198. Minta JO. The role of sialic acid in the functional activity and the hepatic clearance of C1-INH. J Immunol 1981; 126 (1): 245-249
199. Longhurst H. Rhucin, a recombinant C1 inhibitor for the treatment of hereditary angioedema and cerebral ischemia. Curr Opin Investig Drugs 2008; 9 (3): 310-323
200. van Doorn MB, Burggraaf J, van Dam T, et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol 2005; 116 (4): 876-883
201. Raju TS, Scallon BJ. Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain. Biochem Biophys Res Commun 2006; 341 (3): 797-803
202. Dissing-Olesen L, Thaysen-Andersen M, Meldgaard M, et al. The function of the human interferon-beta 1a glycan determined in vivo. J Pharmacol Exp Ther 2008; 326 (1): 338-347
203. Bocci V, Di Francesco P, Pacini A, et al. Renal metabolism of homologous serum interferon. Antiviral Res 1983; 3 (1): 53-58
204. IinoM, Foster DC, Kisiel W. Functional consequences of mutations in Ser-52 and Ser-60 in human blood coagulation factor VII. Arch Biochem Biophys 1998; 352 (2): 182-192
205. Lillicrap D. Extending half-life in coagulation factors: where do we stand? Thromb Res 2008; 122 Suppl. 4: S2-8
206. Jain S, Hreczuk-Hirst DH, McCormack B, et al. Polysialylated insulin: synthesis, characterization and biological activity in vivo. Biochim Biophys Acta 2003; 1622 (1): 42-49
207. Gregoriadis G, Fernandes A, McCormack B, et al. Polysialic acids: potential role in therapeutic constructs. Biotechnol Genet Eng Rev 1999; 16: 203-215
208. Gregoriadis G, Fernandes A, Mital M, et al. Polysialic acids: potential in improving the stability and pharmacokinetics of proteins and other therapeutics. Cell Mol Life Sci 2000; 57 (13-14): 1964-1969
209. Stork R, Zettlitz KA, Muller D, et al. N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. J Biol Chem 2008; 283 (12): 7804-7812
210. Fernandes AI, Gregoriadis G. Polysialylated asparaginase: preparation, activity and pharmacokinetics. Biochim Biophys Acta 1997; 1341 (1): 26-34
211. Fernandes AI, Gregoriadis G. The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: implication in its pharmacokinetics. Int J Pharm 2001; 217 (1-2): 215-224
212. Jelkmann W. The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur J Haematol 2002; 69 (5-6): 265-274
213. Egrie JC, Dwyer E, Browne JK, et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003; 31 (4): 290-299
214. Gross AW, Lodish HF. Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J Biol Chem 2006; 281 (4): 2024-2032
215. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002; 100 (10): 3457-3469
216. Ruman JI, Pollak S, Trousdale RK, et al. Effects of long-acting recombinant human follicle-stimulating hormone analogs containing N-linked glycosylation on murine folliculogenesis. Fertil Steril 2005; 83 Suppl. 1: 1303-1309
217. Trousdale RK, Yu B, Pollak SV, et al. Efficacy of native and hyperglycosylated follicle-stimulating hormone analogs for promoting fertility in female mice. Fertil Steril 2009; 91 (1): 265-270
218. Fauser BC, Mannaerts BM, Devroey P, et al. Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained folliclestimulating activity and reduced injection frequency. Hum Reprod Update 2009; 15 (3): 309-321
219. Loutradis D, Drakakis P, Vlismas A, et al. Corifollitropin alfa, a long-acting follicle-stimulating hormone agonist for the treatment of infertility. Curr Opin Investig Drugs 2009; 10 (4): 372-380
220. Balen AH, Mulders AG, Fauser BC, et al. Pharmacodynamics of a single low dose of long-acting recombinant follicle-stimulating hormone (FSH-carboxy terminal peptide, corifollitropin alfa) in women with World Health Organization group II anovulatory infertility. J Clin Endocrinol Metab 2004; 89 (12): 6297-6304
221. Devroey P, Fauser BC, Platteau P, et al. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab 2004; 89 (5): 2062-2070
222. Duijkers IJ, Klipping C, Boerrigter PJ, et al. Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females. Hum Reprod 2002; 17 (8): 1987-1993
223. Wraith JE. Lysosomal disorders. Semin Neonatol 2002; 7 (1): 75-83
224. Pohl S, Marschner K, Storch S, et al. Glycosylation- and phosphorylationdependent intracellular transport of lysosomal hydrolases. Biol Chem 2009; 390 (7): 521-527
225. Kornfeld S. Lysosomal enzyme targeting. Biochem Soc Trans 1990; 18 (3): 367-374
226. Grabowski GA, Hopkin RJ. Enzyme therapy for lysosomal storage disease: principles, practice, and prospects. Annu RevGenomicsHum Genet 2003; 4: 403-436
227. Murray GJ. Lectin-specific targeting of lysosomal enzymes to reticuloendothelial cells. Methods Enzymol 1987; 149: 25-42
228. Stahl PD, Rodman JS, Miller MJ, et al. Evidence for receptormediated binding of glycoproteins, glycoconjugates, and lysosomal glycosidases by alveolar macrophages. Proc Natl Acad Sci U S A 1978; 75 (3): 1399-1403
229. Furbish FS, Steer CJ, Barranger JA, et al. The uptake of native and desialylated glucocerebrosidase by rat hepatocytes and Kupffer cells. Biochem Biophys Res Commun 1978; 81 (3): 1047-1053
230. Furbish FS, Steer CJ, Krett NL, et al. Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. Biochim Biophys Acta 1981; 673 (4): 425-434
231. Steer CJ, Furbish FS, Barranger JA, et al. The uptake of agalactoglucocerebrosidase by rat hepatocytes and Kupffer cells. FEBS Lett 1978; 91 (2): 202-205
232. McVie-Wylie AJ, Lee KL, Qiu H, et al. Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease. Mol Genet Metab 2008; 94 (4): 448-455
233. Hopwood JJ, Bate G, Kirkpatrick P. Galsulfase. Nat Rev Drug Discov 2006; 5 (2): 101-102
234. Turner CT, Hopwood JJ, Brooks DA. Enzyme replacement therapy in mucopolysaccharidosis I: altered distribution and targeting of alpha-Liduronidase in immunized rats. Mol Genet Metab 2000; 69 (4): 277-285